HC Wainwright reissued their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) in a research note released on Thursday morning, MarketBeat Ratings reports. HC Wainwright currently has a $40.00 price target on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2025 earnings at ($1.12) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.
OKUR has been the topic of several other reports. Oppenheimer began coverage on shares of OnKure Therapeutics in a report on Thursday, October 10th. They set an “outperform” rating and a $35.00 price target on the stock. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th.
View Our Latest Report on OKUR
OnKure Therapeutics Trading Down 3.4 %
OnKure Therapeutics Company Profile
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Further Reading
- Five stocks we like better than OnKure Therapeutics
- There Are Different Types of Stock To Invest In
- AI Boom Fuels Demand for Dominion Energy Stock
- The How And Why of Investing in Oil Stocks
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.